MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Marinus Pharmaceuticals, Inc.

170 North Radnor Chester Road
Suite 250
Radnor, PA 19087
United States
484-801-4670
http://www.marinuspharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees21

Key Executives

NameTitlePayExercisedYear Born
Mr. Christopher Michael CashmanExec. Chairman, CEO & Pres613.1kN/A1957
Mr. Edward F. SmithCFO, VP, Treasurer & Sec.433.5kN/A1971
Dr. Lorianne K. MasuokaChief Medical OfficerN/AN/A1961
Ms. Lisa M. CaperelliExec. Director of Investor & Strategic RelationsN/AN/AN/A
Dr. Kimberly A. McCormickHead of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Corporate Governance

Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 1, 2018 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.